MOXISIGN-D Eye/Ear Drops is a dual-action sterile solution combining a broad-spectrum antibiotic with a potent anti-inflammatory agent to treat bacterial infections and reduce associated inflammation in the eyes or ears. Manufactured under stringent quality standards, it ensures fast and effective relief from pain, swelling, redness, and microbial irritation.

This product is manufactured under the Dr Precision label, ensuring GMP-compliant quality and precision formulation standards.

MOXISIGN-D Eye/Ear Drops is a scientifically designed combination drug therapy that merges the powerful antimicrobial efficacy of Moxifloxacin with the anti-inflammatory and anti-allergic properties of Dexamethasone. This dual-purpose ophthalmic and otic solution is widely indicated for treating infections caused by susceptible bacteria and for reducing inflammation in post-surgical or acute infection conditions affecting the eyes or ears.

Moxifloxacin, a fourth-generation fluoroquinolone antibiotic, acts by inhibiting bacterial DNA gyrase and topoisomerase IV, essential enzymes required for bacterial replication and repair. Its broad-spectrum coverage ensures that both Gram-positive and Gram-negative bacteria are effectively targeted, including strains often resistant to older fluoroquinolones. When used in ophthalmic or otic settings, it provides rapid bacterial eradication and symptom relief, reducing the risk of complications like corneal ulcers or middle ear damage.

Dexamethasone, on the other hand, is a corticosteroid that suppresses inflammatory responses by blocking the release of inflammatory mediators like prostaglandins and leukotrienes. It helps alleviate redness, pain, swelling, and itching associated with bacterial infections and surgical procedures. Together, the two ingredients complement each other: Moxifloxacin treats the root microbial cause, while Dexamethasone addresses the resulting tissue response, promoting quicker and more comfortable recovery for the patient.

MOXISIGN-D is particularly beneficial for patients with conjunctivitis, blepharitis, keratitis, post-operative ocular inflammation, otitis externa, and other bacterial infections where inflammation is a significant component. It is often prescribed after cataract or LASIK surgeries, foreign body removal, or ear cleaning procedures to prevent secondary infections and reduce inflammation. The formulation is pH-balanced, non-irritating, and designed for rapid absorption at the site of infection.

Manufactured by BluepillExpress under WHO-GMP and ISO-certified environments, MOXISIGN-D is produced using aseptic techniques within Class 100 cleanrooms. The formulation undergoes rigorous quality control processes, including sterility testing, antimicrobial effectiveness validation, particulate matter analysis, and pH/osmolality measurement. Each batch is accompanied by a comprehensive Certificate of Analysis (COA), ensuring international export readiness.

The product is packaged in 5 mL or 10 mL LDPE sterile dropper bottles with tamper-evident seals. For sensitive markets, BluepillExpress offers preservative-free versions and customized label printing under private branding. The dropper design ensures precision dosing while minimizing contamination risks. Shelf life typically ranges from 18 to 24 months under controlled room temperature.

MOXISIGN-D is recommended for use in both adults and children under medical supervision. Standard administration involves one to two drops instilled into the affected eye or ear, two to four times daily, depending on the severity of the condition. The duration of treatment is typically limited to 5 to 7 days to prevent steroid overuse and minimize potential side effects such as increased intraocular pressure or fungal overgrowth.

Warnings include avoiding contact between the dropper tip and the infected area, not using the product beyond the recommended duration without physician oversight, and contraindications in individuals with viral or fungal ocular/otic infections. Despite being well-tolerated, prolonged or unsupervised use may lead to local irritation, transient burning sensation, or changes in vision. Patients should be advised to complete the prescribed course even if symptoms improve early.

MOXISIGN-D is widely accepted in both domestic and export markets due to its dual functionality, excellent efficacy profile, and broad indication spectrum. It is an essential component of ophthalmic and ENT therapeutic kits and is favored by practitioners for its simplicity and fast results. The product is aligned with international pharmacopeial standards, making it suitable for registration and distribution across Southeast Asia, the Middle East, Africa, and Latin America.

In conclusion, MOXISIGN-D Eye/Ear Drops by BluepillExpress offers a reliable, potent, and well-formulated treatment for bacterial infections accompanied by inflammation in ocular and otic conditions. It serves as a high-value addition for pharmaceutical distributors and private-label clients seeking a versatile product backed by quality, compliance, and therapeutic confidence.